Hi @Bouncing
The next trial that will start later this year, is an adaptive 2/3 trial for which the FDA has already advised they will consider accelerated approval at the 24 week mid trial results. This I understand is reliant on gaining Orphan Drug Designation status. The shelf life is also considerable so making a bulk batch will not go to waste.
Cheers
Hi @Bouncing The next trial that will start later this year, is...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $91.22M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $323.7K | 1.637M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 576351 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 291638 | 4 |
View Market Depth
| Last trade - 11.27am 25/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |